(Q43101009)

13 November 2017

title

Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis (English)

1 reference

13 November 2017

4

M Petri

1 reference

13 November 2017

C M Lanata

1

1 reference

13 November 2017

T Mahmood

series ordinal

2

1 reference

13 November 2017

D M Fine

series ordinal

3

1 reference

13 November 2017

publication date

13 April 2010

1 reference

13 November 2017

1 reference

13 November 2017

volume

19

1 reference

13 November 2017

issue

8

1 reference

13 November 2017

page(s)

935-940

1 reference

Therapeutic options for resistant lupus nephritis

13 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0961203310365714

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310365714

Lupus nephritis: treatment with mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310365714

Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310365714

Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310365714

Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310365714

The effectiveness and safety of mycophenolate mofetil in lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310365714

A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310365714

FK 506 and mycophenolate mofetil in renal transplant recipients: six-month results of a multicenter, randomized dose ranging trial. FK 506 MMF Dose-Ranging Kidney Transplant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310365714

A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310365714

Hypercoagulability: interaction between inflammation and coagulation in familial Mediterranean fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310365714

Tacrolimus: a further update of its use in the management of organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310365714

Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310365714

Systemic lupus erythematosus in a multiethnic US cohort (LUMINA) XL II: factors predictive of new or worsening proteinuria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310365714

Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310365714

New-onset diabetes mellitus presenting with diabetic ketoacidosis after pediatric liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310365714

A case showing complete insulin independence after severe diabetic ketoacidosis associated with tacrolimus treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310365714

Sudden onset of diabetes with ketoacidosis in a patient treated with FK506/tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310365714

Diabetic ketoacidosis and hyperglycemic hyperosmolar syndrome after renal transplantation in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310365714

Correlation between lipid abnormalities and immunosuppressive therapy in renal transplant recipients with stable renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310365714

Evidence of hypercoagulability and inflammation in young patients long after acute cerebral ischaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310365714

Update on the management of lupus nephritis: let the treatment fit the patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310365714

Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310365714

Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310365714

21 January 2018

Identifiers

DOI

10.1177/0961203310365714

1 reference

13 November 2017

1 reference